Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Satoreotide Tetraxetan,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Ariceum Therapeutics
Deal Size : $26.4 million
Deal Type : Series A Financing
Details : The proceeds from the financing will enable Ariceum to further develop its lead asset and proprietary peptide derivative, 177Lu-OPS201 (satoreotide). Satoreotide is a radiopharmaceutical drug and an antagonist of the somatostatin type 2 (SST2) receptor.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
August 06, 2022
Lead Product(s) : Satoreotide Tetraxetan,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Ariceum Therapeutics
Deal Size : $26.4 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Nephrology
Study Phase : Preclinical
Recipient : Tribune Therapeutics
Deal Size : Undisclosed
Deal Type : Financing
Tribune Therapeutics Launches to Develop Novel Medicines Targeting a Wide Range of Fibrotic Diseases
Details : Based on research from Håvard Attramadal's lab at Oslo University Hospital, Tribune is developing a novel drug with a pan-antifibrotic mechanism of action targeting several fibrotic indications including diseases affecting the kidney, lung and liver.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 06, 2021
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Recipient : Tribune Therapeutics
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Emactuzumab,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : SynOx Therapeutics
Deal Size : $45.0 million
Deal Type : Series A Financing
SynOx Therapeutics raises €37M in Series A Financing
Details : The financing will enable SynOx to continue the development of emactuzumab, for the treatment of diffuse tenosynovial giant cell tumours (“TGCT”), also known as pigmented villonodular synovitis (”PVNS”), and other indications.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
November 19, 2020
Lead Product(s) : Emactuzumab,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : SynOx Therapeutics
Deal Size : $45.0 million
Deal Type : Series A Financing
Reset All
